Matinas BioPharma corrects option exercise price to $1.19

Q: How many shares does MTNB director Edward Neugeboren’s option cover?

The option covers 5,000 Matinas BioPharma common shares and has a $1.19-per-share exercise price. It was granted November 6, 2026, and expires November 6, 2036.

The option vests in full upon the earlier of the one-year anniversary of the grant date or a Change in Control, subject to continued service.

Available on EDGAR 11/09/2026 - 04:05 PM EST Accepted by SEC EDGAR 11/09/2026 - 04:05 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

4/A

Rhea-AI Filing Summary

Matinas BioPharma Holdings, Inc. corrected an administrative error in the reported exercise price for director Edward Neugeboren’s option covering 5,000 common shares. Granted November 6, 2026, the option has a $1.19-per-share exercise price and expires November 6, 2036. It vests in full upon the earlier of the one-year anniversary of the grant date or a “Change in Control,” subject to continued service through the applicable vesting date.

Insider Trade Summary

Grant/Award: 5,000 shares

Grant/Award 1 txn

Insider NEUGEBOREN EDWARD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to Buy) ^{F1, F2}	5,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to Buy) — 5,000 options (Direct)

Holdings Before and After: Stock Option (right to Buy), 0 to 5,000 options (Direct)

Footnotes (2)

F1. This amendment on Form 4/A is being filed to amend the Form 4 filed on November 6, 2026, solely to correct an administrative error in the exercise price of the Stock Option previously reported in Column 2 of Table II.
F2. On November 6, 2026 (the "Grant Date"), the Reporting Person was granted an option to purchase 5,000 shares of the Issuer's common stock, par value $.0001 per share, pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The option will vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) a "Change in Control" (as defined by the Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

Key Figures

Option shares: 5,000 common shares Exercise price: $1.19 per share Grant date: November 6, 2026 +1 more

4 metrics

Option shares 5,000 common shares Option granted to Edward Neugeboren

Exercise price $1.19 per share Option granted November 6, 2026

Grant date November 6, 2026 Option grant

Expiration date November 6, 2036 Option

Key Terms

exercise price, vest in full, Change in Control

3 terms

exercise price financial

"correct the exercise price of the Stock Option"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full technical

"The option will vest in full upon the earlier of"

Change in Control technical

"a “Change in Control” (as defined by the Plan)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares does MTNB director Edward Neugeboren’s option cover?

The option covers 5,000 Matinas BioPharma common shares and has a $1.19-per-share exercise price. It was granted November 6, 2026, and expires November 6, 2036.

When does Edward Neugeboren’s MTNB option vest?

The option vests in full upon the earlier of the one-year anniversary of the November 6, 2026 grant date or a “Change in Control,” subject to Edward Neugeboren’s continued service through the applicable vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEUGEBOREN EDWARD

(Last)

(First)

(Middle)

C/O MATINAS BIOPHARMA HOLDINGS, INC.

1545 ROUTE 206 SOUTH SUITE 302

(Street)

BEDMINSTER

NEW JERSEY

07921

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Matinas BioPharma Holdings, Inc. [ MTNB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/06/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to Buy)	$1.19⁽¹⁾	11/06/2026		A		5,000		⁽²⁾	11/06/2036	Common Stock	5,000	$0	5,000	D

Explanation of Responses:

1. This amendment on Form 4/A is being filed to amend the Form 4 filed on November 6, 2026, solely to correct an administrative error in the exercise price of the Stock Option previously reported in Column 2 of Table II.

2. On November 6, 2026 (the "Grant Date"), the Reporting Person was granted an option to purchase 5,000 shares of the Issuer's common stock, par value $.0001 per share, pursuant to the Issuer's 2025 Equity Incentive Plan (the "Plan"). The option will vest in full upon the earlier of (i) the one-year anniversary of the Grant Date or (ii) a "Change in Control" (as defined by the Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.

	/s/ Jerome D. Jabbour, attorney-in fact for Edward Neugeboren	11/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR